Tomas J. Philipson was appointed Director of Jupiter Neurosciences, Inc. As of November 6, 2026, Jupiter Neurosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 22, 2026 to June 30, 2026, naming 1 appointment and 1 departure (Form 8-K, June 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Jupiter Neurosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Jupiter Neurosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-22 to 2026-06-30. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Jupiter Neurosciences, Inc. files it.
Also on the record for Jupiter Neurosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 26, 2026 | Stake report, Schedule 13G/A, by PharmAla Biotech Holdings Inc. | 10.1% of the class | 5%+ stakes | Source |
| September 22, 2026 | Stake report, Schedule 13G, by PharmAla Biotech Holdings Inc. | 17.3% of the class | 5%+ stakes | Source |
| September 4, 2026 | Form D, private offering | $775K sold | Form D page | Source |
| August 28, 2026 | Stake report, Schedule 13G, by Orca Capital AG | 8.4% of the class | 5%+ stakes | Source |
| August 28, 2026 | Stake report, Schedule 13G/A, by Orca Capital AG | 3.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Jupiter Neurosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Jupiter Neurosciences, Inc. and the records around it.
Jupiter Neurosciences, Inc. elsewhere on the record
- Form D filing Sep 2026
- Who owns it
Companies that share a holder
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
Watch Jupiter Neurosciences, Inc.
Get an email when Jupiter Neurosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Jupiter Neurosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Jupiter Neurosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jupiter Neurosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-30 | In | Director | 8-K, 2026-06-30 | ||
| 2026-06-22 | Out | Director | 8-K, 2026-06-22 |
Who leads Jupiter Neurosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Tomas J. Philipson, appointed (filed 2026-06-30).
New leaders reset buying decisions — get the Full Report on Jupiter Neurosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Jupiter Neurosciences, Inc., with the record behind each one.
Find candidates like Director at Jupiter Neurosciences, Inc.Every change, in the filing's words
Appointed: Tomas J. Philipson, Director
On June 26, 2026, the Board of Directors (the "Board") of Jupiter Neurosciences, Inc. (the "Company") appointed Tomas J. Philipson, Ph.D. to serve as a member of the Board, effective immediately.
- Dr. Philipson will serve until the next annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation, or removal.
- In connection with his appointment, Dr. Philipson was also appointed to serve as a member of the Audit Committee and the Compensation Committee of the Board, in each case effective on the same date as his appointment to the Board.
- Dr. Philipson, age 64, is a health care economist with experience across academia, government, and the private sector.
- Since June 2020, Dr. Philipson has been self-employed through his consulting firm, TJP Economic Consulting Inc., where he advises senior executives at biopharmaceutical and health care companies on economic and policy matters.
- Dr. Philipson currently serves as Managing Partner of MEDA Ventures since 2023.
- Dr. Philipson serves on the advisory boards of Diagnos Inc. since 2025, GATC Health Corp. (Medical Advisory Board) since 2022, iRemedy Healthcare Companies, Inc. since 2021, Epigenetix, Inc. since 2021, Nested Knowledge, Inc. since 2022, and M2i Global, Inc. since 2024.
- He is also a member of the Anthropic Economic Advisory Council since 2025.
- Dr. Philipson co-founded Precision Health Economics LLC in 2007 and served as Managing Partner until its acquisition in 2015.
Departing: Allison W. Brady, Director
On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the "Board") of Jupiter Neurosciences, Inc. (the "Company"), informed the Company of her decision to resign from the Board, effective immediately.
- Ms. Brady also resigned from her positions as a member of the Audit Committee and the Compensation Committee of the Board, effective as of the same date.
- Her decision to resign is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Ms. Brady's seat on the Board will remain vacant until the Company's annual meeting on July 22, 2026.
Tools for this story
Each opens in a new tab, filled in for Jupiter Neurosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.